1. Home
  2. NMCO vs MRVI Comparison

NMCO vs MRVI Comparison

Compare NMCO & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal Credit Opportunities Fund

NMCO

Nuveen Municipal Credit Opportunities Fund

HOLD

Current Price

$10.68

Market Cap

560.1M

Sector

Finance

ML Signal

HOLD

Logo Maravai LifeSciences Holdings Inc.

MRVI

Maravai LifeSciences Holdings Inc.

HOLD

Current Price

$3.09

Market Cap

472.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMCO
MRVI
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
560.1M
472.8M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
NMCO
MRVI
Price
$10.68
$3.09
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$4.00
AVG Volume (30 Days)
126.0K
1.3M
Earning Date
01-01-0001
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.29
EPS
N/A
N/A
Revenue
N/A
$185,743,000.00
Revenue This Year
N/A
$11.80
Revenue Next Year
N/A
$7.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.69
$1.67
52 Week High
$11.20
$4.11

Technical Indicators

Market Signals
Indicator
NMCO
MRVI
Relative Strength Index (RSI) 48.17 40.23
Support Level $10.68 $2.44
Resistance Level $10.74 $3.99
Average True Range (ATR) 0.11 0.21
MACD -0.02 -0.04
Stochastic Oscillator 41.86 10.99

Price Performance

Historical Comparison
NMCO
MRVI

About NMCO Nuveen Municipal Credit Opportunities Fund

Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Share on Social Networks: